Two months after laying off 20% of its staff, Korro Bio says it has not retreated from its “3-2-1” corporate strategy as it prepares to release interim clinical data on its lead candidate KRRO-110 in ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

A group of University of Ottawa researchers have already shown how scientists can harness gene therapies to deliver ...

A fed-batch reaction is harder to design than a batch process because of the need to specify all the variables and quantities.

In July 2025, CereMark Pharma LLC conducted a clinical trial to evaluate the safety and efficacy of [F-18]Flornaptitril-PET (F-18 FNT-PET) for the prediction of clinical progression of Mild Cognitive ...

MENLO PARK, CA, USA & GENEVA, Switzerland I July 23, 2025 I AN2 Therapeutics, Inc. (Nasdaq: ANTX) and the non-profit medical research organization Drugs ...